ELCC is a program of the European Society for Medical Oncology (ESMO ... M.D., CEO of MAIA. "Our poster features our latest findings on cytokine Interleukin-6 (IL-6) as a potential predictive ...

today announces two poster presentations at the European Society for Medical Oncology (ESMO)'s European Lung Cancer Congress 2025 (ELCC 2025). The studies demonstrate how Volition's Nu.Q ...

Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the ...

Poster highlights potential predictive ... ELCC is a program of the European Society for Medical Oncology (ESMO). "We are proud to join ELCC 2025, a premier conference focused directly on the ...

Studies demonstrate how Volition's Nu.Q®H3K27Me3 biomarker, when combined with ctDNA, may improve the prognostic value for overall survival and could help inform treatment decisions in NSCLC; and how ...